Tafenoquine for children: a step towards implementation

After several decades of development, tafenoquine, an 8-aminoquinoline compound, was registered by the US Food and Drug Administration on July 20, 2018, as a single-dose regimen for the prevention of Plasmodium vivax malaria relapse and weekly regimen for the chemoprophylaxis of malaria. The drug is a welcome addition to the antimalarial pharmacopoeia, although several challenges remain before it can be used widely in malaria endemic countries.